Home>Topics>Companies>Quest Diagnostics

Quest Diagnostics DGX

  1. All
  2. Commentary
  3. Headlines
    1. Fitch Rates Quest Diagnostics' Bond Offering 'BBB'; Outlook Stable


      Thu, 5 Mar 2015

      March 05 (Fitch) Fitch Ratings has assigned a 'BBB' rating to the $1.2 billion bond offering by Quest Diagnostics Inc . ( Quest ; NYSE: DGX ). The Rating Outlook is Stable. A full list of ratings follows at the end of this release. Fitch

    2. Quest Sees Robust Volume Growth in 1Q; Raising Our Fair Value Estimate


      Thu, 29 Jan 2015

      Quest Diagnostics posted respectable fourth-quarter results ..... liked the structural characteristics of Quest 's narrow moat and anticipate these will ..... Affordable Care Act. Unfortunately, Quest 's improved volume did not translate

    3. LabCorp Plans for Covance Acquisition; Our Fair Value Estimate Stands


      Mon, 3 Nov 2014

      for the combined company. However, we believe the combined entity will enjoy competitive benefits over key rival Quest Diagnostics , especially over the longer term as the new post-health-care-reform world evolves. We think the strategic

    4. Quest Sees Signs of Improving Business in Third Quarter


      Thu, 23 Oct 2014

      Quest Diagnostics posted respectable third-quarter results ..... suggest volume and pricing are improving for Quest . We stand behind the firm's narrow ..... the moat trend is stable. We applaud Quest 's decision to walk away from unprofitable

    5. Quest Sees Slight Volume Gain in Second Quarter, but Also Faces Price Decline


      Thu, 24 Jul 2014

      Quest Diagnostics released second-quarter performance ..... organic volume growth remains lackluster at Quest . On one hand, quarterly organic volume ..... quarters of declines. On the other hand, Quest continues to trail its main rival LabCorp

    6. Raising Fair Value on Sonic Healthcare to Reflect Growing Offshore Presence


      Wed, 11 Jun 2014

      are reimbursed under Medicare and Medicaid respectively. In the U.S., Sonic remains a minnow compared with Quest Diagnostics and LabCorp, with a market share of about 1.5% versus 15%. The U.S. market remains attractive given expected

    7. Top 10 Purchases and Sales from Our Ultimate Stock-Pickers


      Tue, 3 Jun 2014

      was with Oakmark Equity & Income's elimination of Quest Diagnostics DGX "> DGX . Clyde McGregor noted the following in his ..... and three that didn’t (Encana, Hospira and Quest Diagnostics )... In the case of Encana and Quest Diagnostics

    8. LabCorp's First-Quarter Volume Was Solid, but Pricing Took a Hit


      Mon, 28 Apr 2014

      molecular pathology codes and sequestration. As with Quest Diagnostics , we anticipate the pressure should lift somewhat now ..... believe this sets LabCorp apart from its largest rival Quest . LabCorp is on the cusp of rolling out its Beacon LBS

    9. Quest Diagnostics Posts Anemic 1Q, and Our Fair Value Estimate Is Unchanged


      Thu, 24 Apr 2014

      Quest Diagnostics posted tepid first-quarter performance ..... the quarter to change our thinking on Quest 's narrow economic moat. Although the ..... these slightly more positive trends, Quest 's operating margin fell yet again

    10. Oakmark Equity and Income Fund Letter to Shareholders


      Tue, 8 Apr 2014

      t (Encana, Hospira and Quest Diagnostics ). Cimarex and Concho are ..... position. In the case of Encana and Quest Diagnostics , fundamental underperformance ..... redeploy the money elsewhere. With Quest , its weakening market

    « Prev12345Next »
    Content Partners